

✓
Please cancel claim 11.

Please amend claims 1, 3, and 10 to read as follows:

D¹
1. (Three Times Amended) An oligonucleotide comprising a contiguous stretch of at least about 30 nucleotides of at least one of SEQ ID NOS:9, 10, 12, 13, 17, and 18.

D²
3. (Three Times Amended) An isolated polynucleotide comprising a contiguous stretch of at least about 60 nucleotides of at least one of SEQ ID NOS: 9, 10, 12, 13, 14, and 16-18.

D³
10. (Twice Amended) An oligonucleotide comprising a contiguous stretch of at least about 20 nucleotides of SEQ ID NO:16.

Please add claim 12 as follows:

D⁴
12. (New) An isolated polynucleotide consisting essentially of a contiguous stretch of at least about 125 nucleotides of SEQ ID NO:11 or 15.

REMARKS

Claims 1, 3, 4, 10, and 12 are pending in the instant application. Claim 11 has been canceled without prejudice. Applicants reserve the rights to prosecute the canceled subject matter in related applications. Applicants submit that Claims 1, 3, and 10 have been amended and new claim 12 has been added to particular point out and distinctly claim the subject matter which the inventors regard as the invention. The amendments are fully supported by the specification and claims as originally filed. The amended claims are supported in the specification, *inter alia*, at page 16, line 4. New claim 12 is supported in the specification, *inter alia*, at page 4, line 9. Claim 11 is objected to for depending on a non-elected claim, claim 5. Claim 11 has been canceled. As such, the objection is obviated.

I. THE REJECTION UNDER 35 U.S.C. §112, SECOND PARAGRAPH IS OBVIATED

Claim 10 is rejected under 35 U.S.C. § 112, second paragraph as allegedly being indefinite for failing to particular point out and distinctly claim the subject matter which applicant regards as the invention. Claim 10 has been amended to recite an